Increased Odds of Leaving ED Before Medically Advised Tied to COVID-19 Pandemic
By Elana Gotkine HealthDay Reporter
MONDAY, Feb. 24, 2025 -- In the United States, the COVID-19 pandemic was associated with increased odds of leaving the emergency department before medically advised (BMA), according to a study published in the April issue of the American Journal of Emergency Medicine.
Yahya Alnashri, M.D., M.P.H., from Prince Sattam bin Abdulaziz University in Al-Kharj, Saudi Arabia, and colleagues conducted a cross-sectional study using data from the National Hospital Ambulatory Medical Care Survey from 2016 to 2021 to examine factors associated with leaving BMA from emergency departments.
Overall, 5.9 million (0.8 percent) of 721.0 million emergency department visits resulted in leaving BMA. The researchers found that the odds of leaving BMA were increased in association with public or no insurance coverage (Medicare, Medicaid/CHIP/state-based, uninsured/self-pay: adjusted odds ratios, 1.74, 1.86, and 1.51, respectively), alcohol or substance use disorders (adjusted odds ratio, 2.19), arrival by ambulance (adjusted odds ratio, 1.68), and being male (adjusted odds ratio, 1.32). Lower odds of leaving BMA were seen in association with hospital admissions and trauma or overdose-related visits (adjusted odds ratios, 0.11 and 0.54, respectively). Significantly increased odds of leaving BMA were seen in association with the COVID-19 pandemic (adjusted odds ratio, 1.44), with an overall increase of 53.6 percent in BMA-related emergency department visits post-March 2020 versus previous years.
"These findings highlight the need for targeted interventions to improve patient-provider communication and ED triage efficiency, especially in resource-constrained facilities serving lower-income individuals," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-02-25 06:00
Read more
- Boehringer Ingelheim’s Novel Glucagon/GLP-1 Dual Agonist Survodutide Achieved Significant Weight Loss and Meaningful Metabolic Improvement in Phase III Trial
- FDA Approves Inqovi in Combination with Venetoclax, the First All-Oral Combination Treatment for Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction Chemotherapy
- Adding Weekly GLP-1 to Cognitive Behavioral Therapy Further Reduces Heavy Drinking
- Semaglutide May Improve Motivation With Major Depressive Disorder
- AACR: 2020 to 2024 Saw Drop in Number of Unique Lung Cancer Trial Sites
- Patients Wait About 50 Days on Average for First Visit to Neurologist
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions